Cargando…

Retrospective Analysis of the Efficacy of Dapagliflozin in Patients with Type 2 Diabetes in a Primary Clinic in Korea

BACKGROUND: We aimed to retrospectively analyze the efficacy of 10 mg dapagliflozin (DAPA), which is a sodium-glucose cotransporter-2 inhibitor, in Korean patients with type 2 diabetes who visited a primary diabetes clinic. METHODS: In total, 83 patients with type 2 diabetes, who received treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Sang Hyun, Choi, Young Ju, Rhee, Eun-Jung, Huh, Kab Bum
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Endocrine Society 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435850/ https://www.ncbi.nlm.nih.gov/pubmed/30912340 http://dx.doi.org/10.3803/EnM.2019.34.1.70

Ejemplares similares

Predictors for successful weight reduction during treatment with Dapagliflozin among patients with type 2 diabetes mellitus in primary care
por: Huh, Youn, et al.
Publicado: (2022)

Use of dapagliflozin in patients with advanced diabetic kidney disease
por: Park, Hyun Sun, et al.
Publicado: (2018)

Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add‐on to metformin in patients with type 2 diabetes
por: Müller‐Wieland, Dirk, et al.
Publicado: (2018)

Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea
por: Han, Eugene, et al.
Publicado: (2018)

The Prevalence and Risk of Type 2 Diabetes in Adults with Disabilities in Korea
por: Jung, Inha, et al.
Publicado: (2020)

The clinical efficacy and safety of dapagliflozin in patients with diabetic nephropathy
por: Huang, Ying, et al.
Publicado: (2022)

Efficacy of Low-dose Dapagliflozin in Young People with Type 1 Diabetes
por: Urakami, Tatsuhiko, et al.
Publicado: (2023)

Use and effectiveness of dapagliflozin in patients with type 2 diabetes mellitus: a multicenter retrospective study in Taiwan
por: Chen, Jung-Fu, et al.
Publicado: (2020)

Comparative cardiovascular outcomes in type 2 diabetes patients taking dapagliflozin versus empagliflozin: a nationwide population-based cohort study
por: Lim, Jaehyun, et al.
Publicado: (2023)

Efficacy of Gemigliptin Add-on to Dapagliflozin and Metformin in Type 2 Diabetes Patients: A Randomized, Double-Blind, Placebo-Controlled Study (SOLUTION)
por: Lee, Byung Wan, et al.
Publicado: (2023)

A randomized study to establish the effects of spirulina in type 2 diabetes mellitus patients
por: Lee, Eun Hee, et al.
Publicado: (2008)

Dapagliflozin: A Review in Type 2 Diabetes
por: Dhillon, Sohita
Publicado: (2019)

Dapagliflozin: A Review in Type 1 Diabetes
por: Paik, Julia, et al.
Publicado: (2019)

The efficacy of dapagliflozin for type 1 diabetes: a meta-analysis of randomized controlled studies
por: Ma, Jian, et al.
Publicado: (2021)

Abstract 52: Clinical efficacy of dapagliflozin in patients with newly diagnosed type 2 diabetes
por: Patil, Surekha Mahesh
Publicado: (2022)

Comparison of safety and efficacy of dapagliflozin and empagliflozin in type 2 diabetes mellitus patients in India
por: Varshney, Amit, et al.
Publicado: (2023)

Effıcacy and safety of dapagliflozin on diabetic patients receiving high-doses of insulin
por: Sertbas, Meltem, et al.
Publicado: (2019)

2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea
por: Kim, Mee Kyoung, et al.
Publicado: (2019)

Dapagliflozin attenuates diabetes-induced diastolic dysfunction and cardiac fibrosis by regulating SGK1 signaling
por: Lee, Seul-Gee, et al.
Publicado: (2022)

Effect of Dapagliflozin in Combination with Lobeglitazone and Metformin in Korean Patients with Type 2 Diabetes in Real-World Clinical Practice
por: Seo, Da Hea, et al.
Publicado: (2022)

A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy Subjects
por: Kim, Hyun Chul, et al.
Publicado: (2023)

Optimal Waist Circumference Cutoff Value Based on Insulin Resistance and Visceral Obesity in Koreans with Type 2 Diabetes
por: Lim, Jung Soo, et al.
Publicado: (2015)

Characteristics of Type 2 Diabetes in Terms of Insulin Resistance in Korea
por: Park, Jong-Suk, et al.
Publicado: (2005)

Correction to: Dapagliflozin: A Review in Type 1 Diabetes
por: Paik, Julia, et al.
Publicado: (2019)

Correction to: Dapagliflozin: A Review in Type 2 Diabetes
por: Dhillon, Sohita
Publicado: (2019)

Dapagliflozin: an effective adjunctive treatment in type 1 diabetes
por: Yadegarfar, Ghasem, et al.
Publicado: (2021)

Nephroprotective Effects of Dapagliflozin in Patients with Type 2 Diabetes
por: Iijima, Yasuhiro, et al.
Publicado: (2023)

Effect of the Sodium-Glucose Cotransporter 2 Inhibitor, Dapagliflozin, on Genitourinary Infection in an Animal Model of Type 2 Diabetes
por: Choi, Jin Bong, et al.
Publicado: (2020)

Effect of Dapagliflozin on Alanine Aminotransferase Improvement in Type 2 Diabetes Mellitus with Non-alcoholic Fatty Liver Disease
por: Choi, Dug-Hyun, et al.
Publicado: (2018)

2021 Clinical Practice Guidelines for Diabetes Mellitus in Korea
por: Hur, Kyu Yeon, et al.
Publicado: (2021)

Prevalence of Primary Immunodeficiency in Korea
por: Rhim, Jung Woo, et al.
Publicado: (2012)

Ketoacidosis with euglycemia in a patient with type 2 diabetes mellitus taking dapagliflozin: A case report
por: Yeo, Sang Mok, et al.
Publicado: (2019)

Diabetes Epidemics in Korea: Reappraise Nationwide Survey of Diabetes "Diabetes in Korea 2007"
por: Park, Ie Byung, et al.
Publicado: (2013)

Letter: A Retrospective Study on the Efficacy of a Ten-Milligram Dosage of Atorvastatin for Treatment of Hypercholesterolemia in Type 2 Diabetes Mellitus Patients (Korean Diabetes J 2010;34:359-67)
por: Rhee, Eun-Jung
Publicado: (2011)

Individualized diabetes nutrition education improves compliance with diet prescription
por: Lim, Hae-mi, et al.
Publicado: (2009)

Smoking Is Associated With Abdominal Obesity, Not Overall Obesity, in Men With Type 2 Diabetes
por: Yun, Ji Eun, et al.
Publicado: (2012)

Body Mass Index, Diabetes, and Risk of Tuberculosis: A Retrospective Cohort Study
por: Choi, Hayoung, et al.
Publicado: (2021)

Glycated Hemoglobin, Body Weight and Blood Pressure in Type 2 Diabetes Patients Initiating Dapagliflozin Treatment in Primary Care: A Retrospective Study
por: Wilding, John, et al.
Publicado: (2016)

Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes
por: Shin, Seok Joon, et al.
Publicado: (2016)

Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
por: List, James F., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_oq73stvu9bjkal1boqbtl2tblc